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Abstract
By causing damage to neural networks, spinal cord injuries (SCI) often result in severe motor and sensory dysfunction.
Functional recovery requires axonal regrowth and regeneration of neural network, processes that are quite limited in the
adult central nervous system (CNS). Previous work has shown that SCI lesions contain an accumulation of activated
microglia, which can have multiple pathophysiological influences. Here, we show that activated microglia inhibit axonal
growth via repulsive guidance molecule a (RGMa). We found that microglia activated by lipopolysaccharide (LPS) inhibited
neurite outgrowth and induced growth cone collapse of cortical neurons in vitro—a pattern that was only observed when
there was direct contact between microglia and neurons. After microglia were activated by LPS, they increased expression
of RGMa; however, treatment with RGMa-neutralizing antibodies or transfection of RGMa siRNA attenuated the inhibitory
effects of microglia on axonal outgrowth. Furthermore, minocycline, an inhibitor of microglial activation, attenuated the
effects of microglia and RGMa expression. Finally, we examined whether these in vitro patterns could also be observed in
vivo. Indeed, in a mouse SCI model, minocycline treatment reduced the accumulation of microglia and decreased RGMa
expression after SCI, leading to reduced dieback in injured corticospinal tracts. These results suggest that activated
microglia play a major role in inhibiting axon regeneration via RGMa in the injured CNS.
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Introduction
Spinal cord injuries (SCI) often have devastating impacts on
neural function, leading to reductions in motor and sensoryabilities.
These canbecompensatedforvia regeneration ofneuronsand their
axons; however, axonal regeneration in the adult central nervous
system (CNS) is quite limited due to the presence of a number of
axon growth inhibitors. These include myelin-associated proteins
expressedbyoligodendrocytes and chondroitinsulfate proteoglicans
expressed by astrocytes [1]. Over the past decade, a number of
studies have examined whether inhibition of these glial factors is a
viable option for treating CNS injuries. Although these methods did
enhance functional recovery to some extent [2,3], the treatments
were by no means uniformly successful.
SCI causes extensive inflammation and the invasion of a large
number of microglia/macrophages to the epicenter of the lesion. It
is currently unclear whether this influx of cells plays a protective or
a detrimental role during recovery [4–9]. In support of the latter
possibility, recent evidence has indicated that, along with myelin
and glial scarring, activated microglia/macrophages are one of the
major inhibitors of axonal regeneration. For example, activated
macrophages have been shown to induce retraction of dystrophic
axons, both in vitro and in vivo [10]. It was further demonstrated
that MMP-9 inhibitor and chondroitinase ABC prevented
macrophage-induced axonal retraction [11]. Additionally, dieback
of injured axons was suppressed following treatment with
minocycline, which inhibits activation of microglia/macrophages
[12]. However, the key molecules involved in these processes have
yet to be determined.
One group of candidates is the repulsive axon guidance
molecules, which play an important role in precisely directing
the navigation of growing axons during neural development.
These molecules are expressed or re-expressed after adult CNS
injuries and inhibit regeneration of the injured axons [13,14]. In
addition to astrocytes and oligodendrocytes, microglia and
macrophages express guidance molecules that retract the axons,
including Slit, Netrin-1, and repulsive guidance molecule a
(RGMa), in the injured spinal cord [15,16]. Of these, RGMa is
particularly interesting. It is a glycosylphosphatidylinositol (GPI)-
anchored glycoprotein that was originally identified as the
molecule that collapses the growth cone and repels axons during
development [17,18]. RGMa expression increases after SCI,
during which time inhibition of RGMa enhances axonal growth
and motor function recovery [16].
In this study, we aimed to identify the role of microglia in
axonal regeneration and its underlying molecular mechanism. We
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25234found that microglia mediate the inhibition of axon growth, and
that this process involves RGMa.
Materials and Methods
Cell culture
Neurons were harvested from the cerebral cortices of C57BL/6J
mice (Charles River, Yokohama, Japan) at embryonic day 18
(E18). Cortical cells were dissociated by incubation with 0.25%
trypsin and 0.5 mg/ml DNase (Sigma-Aldrich, St. Louis, MO) for
15 min at 37uC, after which they were washed and triturated in
DMEM containing 10% fetal bovine serum (FBS). The neurons
were cultured with DMEM supplemented with 10% FBS and 1%
penicillin/streptomycin in poly-L-lysine-coated dishes at a density
1610
5 cells/ml.
Primary microglial cells were obtained from C57BL/6J mice on
postnatal day 3 (P3) as previously described [19]. Briefly, the
cerebral cortex of each mouse was digested with 0.25% trypsin
and 0.5 mg/ml DNase for 15 min at 37uC. Cells were passed
through a 70-mm nylon mesh. The resultant cell suspension was
diluted with 10% FBS/1% penicillin and streptomycin/DMEM
and seeded into poly-L-lysine-coated dishes. After 10 days, the
dishes were shaken so that floating microglial cells could be
collected from the astrocyte-monolayer sheet and then cultured in
10% FBS/1% penicillin and streptomycin/DMEM at a density
1610
5 cells/ml. In this assay, more than 95% of the cells were
CD11b-positive microglial cells.
Bone marrow-derived macrophages (BMDM) were obtained
from bilateral femurs of adult C57BL/6J mice as previously
reported [20]. Marrow cores were flushed using syringes filled with
RPMI1640/10% FBS. After trituration, cells were washed once in
media, then plated and cultured in RPMI1640 with 10% FBS, 1%
penicillin/streptomycin, and M-CSF (50 ng/ml; Sigma-Aldrich).
Non-adherent cells were collected at day 4. In this assay, more
than 95% of the cells were CD11b-positive macrophages.
Neurite outgrowth assay
Cortical neurons were co-cultured with primary microglia or
BMDM on chamber slides (Lab Tek II; Nunc, Rochester, NY) or
in transwell plates (pore size: 3 mm; Corning, Glendale, AZ) with
10% FBS/1% penicillin and streptomycin/DMEM. To activate
primary microglia and BMDM, lipopolysaccharide (LPS; Sigma-
Aldrich) was added to the culture at a concentration of 1 mg/ml.
Rabbit anti-RGMa antibody (10 mg/ml; IBL, Fujioka, Japan;
[16]) was added for the neutralizing assay. Microglia were treated
with 20 mM minocycline (Sigma-Aldrich) to inhibit activation. The
cells were fixed in 4% paraformaldehyde (PFA) and immuno-
stained with a mouse monoclonal antibody recognizing bIII
tubulin (TuJ1; 1:1,000; Covance; Princeton, NJ) as the primary
antibody and Alexa 488 anti-mouse IgG antibody (1:500;
Invitrogen, Carlsbad, CA) as the secondary antibody. The length
of the longest neurite of each TuJ1-positive neuron was then
determined using ImageJ software (National Institutes of Health,
Bethesda, MD). Data were collected from 3 independent
experiments, in each of which 100 neurons were counted per
group. The length in each group relative to that of control
(neurons-only) was then calculated.
Collapse assay
To visualize growth cones, neurons were fixed for 20 min with
4% PFA and stained with rhodamine-conjugated phalloidin
(1:500; Invitrogen) and anti-TuJ1 (1:1,000; Covance). Growth
cones were designated as ‘‘collapsed’’ if they had lost lamellipodia
and #2 filopodia [21]. Data were collected from 3 independent
experiments, in each of which 50 growth cones were counted per
group. To calculate the percentage of collapse, the number of
collapsed growth cones was divided by the total number of growth
cones.
Lipofection with siRNA
Transfection experiments with mouse RGMa siRNA (stealth
siRNA, Invitrogen) and negative control siRNA (Applied Biosys-
tems, Tokyo, Japan) for primary microglia were performed using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. Microglial cells were stimulated with LPS at 48 h and
lysed at 72 h after transfection for Western blotting. For co-culture
assay, 72 h after siRNA transfection, microglial cells were co-
cultured with cortical neurons with LPS. The sense and antisense
strands of RGMa siRNA were 59-AACAGAUGCAGCUUGUC-
CUUGUUGG-39 and 59-CCAACAAGGACAAGCUGCAUCU-
GUU-39, respectively.
Nucleofection of mouse cortical neurons
Cortical neurons were suspended in 100 ml of Nucleofector
solution (Amaxa Biosystems, Cologne, Germany) containing 250
pmol of mouse neogenin siRNA (Sigma-Aldrich) or negative
control siRNA. Electroporation was performed by using program
O-005 as described by the manufacturer’s protocol (Amaxa
Biosystems). Cortical neurons were lysed at 72 h after transfection
for Western blotting. For co-culture assay, 72 h after siRNA
transfection, cortical neurons were co-cultured with microglial
cells. The sense and antisense strands of neogenin siRNA were 59-
CAAUUCCAUGGAUAGCAAUTT-39 and 59-AUUGCUAUC-
CAUGGAAUUGTT-39, respectively.
Western blot
The cells were lysed in lysis buffer containing 50 mM Tris–HCl
(pH 7.8) with 150 mM NaCl, 1 mM EDTA, 2 mM Na3VO4,1 %
NP-40, and protease inhibitor cocktail (Roche, Palo Alto, CA).
The severed spinal cord (from 1 mm rostral to 1 mm caudal
[2 mm long] to the lesion epicenter) was dissected and
homogenized in lysis buffer. The lysates were incubated on a
rocking platform at 4uC for 20 min and clarified by centrifugation
at 13,000 g at 4uC for 20 min. Supernatants were collected,
separated on SDS-PAGE gels, and transferred to a PVDF
membrane (Millipore, Billerica, MA). The membranes were
blocked with 5% nonfat dry milk in PBS containing 0.05%
Tween-20 (PBST), then incubated with rat anti-RGMa antibody
(1:250; R&D, Minneapolis, MN), rabbit anti-neogenin antibody
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), or mouse
anti-actin antibody (1:5000; Calbiochem, Darmstadt, Germany)
overnight at 4uC. After being washed, membranes were incubated
with HRP-linked anti-rat IgG antibody (1:5000; Cell Signaling
Technology, Beverly, MA), HRP-linked anti-rabbit IgG antibody
(1:5000; Cell Signaling Technology), or HRP-linked anti-mouse
IgM antibody (1:10000; Santa Cruz Biotechnology). Antibodies
were detected using an ECL chemiluminescence system (GE
Healthcare, Buckinghamshire, UK).
Procedures for SCI and treatment
Eight-week-old adult female C57BL/6J mice were deeply
anesthetized with somnopentyl (50 mg/kg, i.p.; Kyoritsu Seiyaku,
Tokyo, Japan). A laminectomy was performed at T9 to expose the
dorsal aspect of the spinal cord. Dorsal hemisection was performed
at this level with a blade to completely sever the dorsal and
dorsolateral corticospinal tracts (CSTs; depth: 1.0 mm). The
muscle layers and skin on the back were then sutured. Minocycline
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25234(50 mg/kg, i.p.; Sigma-Aldrich) was administered for 7 or 14
consecutive days after the surgery. Control groups received
equivolumetric intraperitoneal injections of PBS at the corre-
sponding time points. All surgical procedures and postoperative
care were performed in accordance with the guidelines of the
Osaka University Animal Care and Use Committee.
Anterograde labeling of the CST
One day or 1 week before the SCI, mice were anesthetized with
somnopentyl (50 mg/kg, i.p.) and placed on a stereotaxic frame.
Their scalps were incised so that the region of the skull overlying
the sensorimotor cortex could be carefully split open with a drill.
To label the CST, the anterograde tracer biotinylated dextran
amine (BDA; MW, 10,000; 10% in PBS; Invitrogen), was injected
at a total of 8 sites per individual (4 sites per side and 0.6 ml per site
over 3 30-s injection cycles) at a depth of 0.5 mm from the cortical
surface (coordinates: 1.0–1.5 mm posterior, 0.5–1.0 mm lateral to
the bregma) by using a 5-ml microsyringe tipped with a pulled glass
micropipette. After the injections, the skin overlying the skull was
sutured.
Immunohistochemistry
The animals received a transcardial perfusion of 4% PFA at 7 or
14 days after the SCI. Spinal cords were dissected and postfixed in
the same fixative overnight. On the following day, the tissue was
cryopreserved in 30% sucrose/PBS. Thoracic spinal cords were
Figure 1. Transected axons do not regrow into the lesion of SCI
where microglia/macrophages accumulate. A, B, Immunostaining
of phospho-neurofilament (SMI31; A; axon, green) and CD11b (B;
microglia/macrophage, red) at day 7 after SCI. Scale bar: 500 mm. C–E,
BDA-labeled CST fibers (C, green) and CD11b (D; microglia/macrophage,
red) at day 7 after SCI. Scale bar: 500 mm.
doi:10.1371/journal.pone.0025234.g001
Figure 2. Activated microglia inhibit neurite outgrowth and induce growth cone collapse in vitro. A, Relative length of neurites of
cortical neurons, neurons stimulated by LPS, and neurons co-cultured with BMDM, BMDM stimulated by LPS, microglia, or activated microglia
stimulated by LPS (n=3). B–D, Representative figures of neurons (TuJ1, green, B), neurons co-cultured with unactivated microglia (C), and neurons co-
cultured with activated microglia (D). Scale bar: 20 mm. E, Collapse assay (n=3). F–H, Representative figures of growth cones (phalloidin staining, red)
of a neuron (F), a neuron co-cultured with unactivated microglia (G), and a neuron co-cultured with activated microglia (H). Scale bar: 10 mm. Data are
represented as mean 6 SEM. *p,0.01 (one-way ANOVA followed by Tukey-Kramer test).
doi:10.1371/journal.pone.0025234.g002
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Tokyo, Japan). Serial 14- or 20-mm-thick sagittal sections were
cut with a cryostat and mounted on MAS-coated slides
(Matsunami Glass, Osaka, Japan). Sections were blocked with
5% BSA/0.1% Triton X-100/PBS for 1 h and then incubated
with the following primary antibodies overnight at 4uC: rat anti-
CD11b (1:250; Serotec, Kidlington, UK), rabbit anti-RGMa
(1:100; IBL), and mouse anti-phospho-neurofilament (SMI31;
1:1000; Covance). Sections were washed with PBST, then
incubated with the following secondary antibodies for 1 h at
room temperature: Alexa Fluor 488 or Alexa Fluor 568 goat anti-
rat IgG, goat anti-rabbit IgG, and goat anti-mouse IgG (1:500;
Invitrogen). For BDA labeling, the sections were incubated at
room temperature in 5% BSA/0.1% Triton X-100/PBS for 1 h,
then with Alexa Fluor 488-conjugated streptavidin (1:500;
Invitrogen) for 2 h. The sections were then washed with PBST
and counterstained with DAPI (1 mg/ml; Santa Cruz Biotechnol-
ogy) to allow visualization of the nuclei. All images were acquired
with a fluorescence microscope (Olympus BX51, DP71; Tokyo,
Japan) or a confocal laser-scanning microscope (Olympus Fluo-
View FV1000).
Accumulation of microglia was assessed in three parasagittal
CD11b-immunostained sections per animal. The positive area was
measured by using ImageJ software and averaged. To quantify the
dieback of the dorsal CST, the distance between the margin of
lesion defined by accumulation of CD11b
+ cells and the tips of the
BDA-labeled CST axons (bulbous in appearance) was measured in
one parasagittal section per animal (10 axons per section) and
averaged. The border of accumulation of CD11b
+ cells [22],
which was determined automatically with ImageJ software (NIH),
is approximately corresponded to the margin of lesion as the
border between GFAP positive and negative site (astroglial and
fibrotic scar), the definition used in previous studies [23,24].
Statistics
Quantitative data are expressed as the mean 6 SEM. We
investigated differences across all groups using one-way analysis of
variance (ANOVA) tests, followed by Tukey-Kramer tests. We
explored differences between pairs of experimental groups using
Student’s t-tests. Significance was defined as P,0.05.
Results
Activated microglia inhibit neurite outgrowth and induce
growth cone collapse
At 7 days after SCI, transected axons were retracted and did not
grow into the lesion site (Figure 1A). The lesion epicenter
neighboring these retracted axons was composed of a number of
CD11b
+ cells, which were activated microglia or macrophages
(Figure 1A, B). The transected CST, one of the major axonal tracts
controlling fine motor function, was also retracted from the lesion
site containing CD11b
+ cells (Figure 1C–E). Thus, it appears likely
that these cells affect nearby neurons. To assess the effect of
microglia or macrophage on the neurons, we employed co-culture
assay consisting of cortical neurons (E18) and microglia/
macrophage in vitro. Co-culture assay revealed that neurite
outgrowth tended to be slightly promoted when neurons were
cultured with primary microglia or BMDM for 2 days, but
statistically not significant (Figure 2A–C). However, when the
neurons were cultured with microglia activated by LPS, neurite
outgrowth was significantly inhibited (P,0.01; Figure 2A–D).
Additionally, the growth cones of these neurons were collapsed
(P,0.01; Figure 2E–H). LPS itself did not modulate neurite
outgrowth and growth cone morphology (Figure 2A, E). On the
other hand, BMDM activated by LPS did not inhibit neurite
outgrowth, but rather slightly increased the neurite length than
non-stimulated BMDM (statistically not significant; Fig. 2A). These
results suggest that activated primary microglia, but not BMDM
or unactivated microglia, inhibit neurite growth and induce
growth cone collapse.
Cell-cell contact is necessary for the inhibitory activity of
activated microglia
We hypothesized that some molecules expressed in the activated
microglia inhibited neurite growth and collapsed growth cones.
These molecules may be secreted from the activated microglia. To
Figure 3. Cell-cell contact is necessary for activated microglia-induced neurite outgrowth inhibition and growth cone collapse. A,
Results of neurite outgrowth assay across 4 treatment groups (neurons-only, neurons + LPS, neurons co-cultured with unactivated microglia, neurons
co-cultured with activated microglia) in the transwell system (n=3). The neurons, seeded to the lower plane, were separately co-cultured with the
unactivated and activated primary microglia, seeded to the upper plane. B, Results of growth cone collapse assay across 4 treatment groups
(neurons-only, neurons + LPS, neurons co-cultured with unactivated or activated microglia) in the transwell system (n=3). Data are represented as
mean 6 SEM.
doi:10.1371/journal.pone.0025234.g003
The Role of Microglial RGMa
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25234The Role of Microglial RGMa
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25234assess this, the neurons were separately co-cultured with the
activated primary microglia in the transwell system. In contrast to
our co-culture results (Figure 2), LPS-stimulated microglia had no
effect on either neurite length or growth cone collapse (Figure 3A,
B) in transwell plates. These results suggest that, adhesion
molecules, rather than secreted molecules, should be responsible
for the effects of microglia on neurite growth.
RGMa mediates the effect of activated microglia
Microglia express guidance molecules that are known to repel
the axons, e.g. Slit, Netrin-1, and RGMa, in injured spinal cord
[15,16]. Given that microglia inhibit axonal growth via cell-cell
contact (Figure 2, 3), we assessed if RGMa was involved in the
effects. Indeed, RGMa was expressed in microglia and the
expression was increased by LPS induction (P,0.01; Figure 4A, B).
We employed anti-RGMa antibodies to attenuate the effect of
RGMa [16,25]. The addition of anti-RGMa antibodies dramat-
ically reduced neurite outgrowth inhibition and growth cone
collapse (P,0.01; Figure 4C, D). An antibody-only control
treatment had no effect on neurite outgrowth or growth cone
collapse. Next, we transfected RGMa siRNA or control non-
targeting siRNA into primary microglia, and employed co-culture
assay consisting of cortical neurons and microglia. RGMa siRNA
efficiently reduced the expression of RGMa in activated microglia
stimulated with LPS (P,0.01; Figure 4E, F). When the neurons
were co-cultured with activated microglia transfected with RGMa
siRNA, neurite outgrowth inhibition and growth cone collapse
induced by activated microglia was decreased (P,0.01; Figure 4G,
H). This effect was not observed in control siRNA-transfected
microglia. These results indicate that RGMa mediates the effects
of activated microglia on cortical neurons.
We further transfected neogenin, a receptor for RGMa, siRNA or
control non-targeting siRNA into cortical neurons, and employed co-
culture assay consisting of cortical neurons and microglia. Neogenin
siRNA efficiently reduced the expression of neogenin in cortical
neurons (P,0.01; Figure 4I, J). When the neurons transfected with
neogenin siRNA were co-cultured with activated microglia, neurite
outgrowth inhibition and growth cone collapse induced by activated
microglia were decreased (P,0.01; Figure 4K, L). This effect was not
observed in control siRNA-transfected neurons. These results
indicate that RGMa-neogenin signal transduction is required for
the effects of activated microglia on cortical neurons.
Minocycline rescues activated microglia-induced neurite
outgrowth inhibition and growth cone collapse
Minocycline inhibits microglial activation [12,26]. This prompt-
ed us to investigate whether minocycline treatment could rescue
the neurite growth inhibition induced by activated microglia and
RGMa. Western blot analysis revealed that minocycline efficiently
suppressed the increase of RGMa expression in activated
microglia (P,0.01; Figure 4A, B). The neurons and microglia
were co-cultured with or without the addition of minocycline
(20 mM) for 2 days. It was found that neurite outgrowth inhibition
and growth cone collapse were reduced to control levels in neuron-
microglia co-cultures that were treated with minocycline (P,0.01;
Figure 4M, N). Minocycline by itself had no effect on neurite
outgrowth and growth cone collapse in the neurons. Therefore,
minocycline inhibits the effects of activated microglia on the
neurite outgrowth and RGMa expression.
Blockage of microglial activation inhibits CST dieback
with the reduction of RGMa expression
We attempted to investigate the role of RGMa in microglia in
vivo by employing mice SCI model. Intensive RGMa expression
was found in CD11b-positive cells in the lesion epicenters of SCI
mice; furthermore, this expression was significantly increased
during the subacute phase of SCI (Figure 5A–C). Then, we
administrated minocycline (50 mg/kg, i.p.) to mice for 7 or 14
consecutive days after SCI to inhibit microglial activation. Mice
treated with minocycline accumulated significantly fewer CD11b-
positive cells in their lesion sites (P,0.05; Figure 5D–H).
Consistent with our observations in vitro (Figure 4A, B),
minocycline treatment dramatically decreased the expression of
RGMa, as measured at 7 days after SCI (P,0.01; Figure 5B, C).
Then, we assessed the morphological changes in the transected
CST. We observed dieback of CST from the lesion site at 7 and 14
days after SCI; however, this distance was significantly decreased
by the minocycline treatment (P,0.05; Figure 5I–M). These
results support our hypothesis that RGMa mediates the effects of
activated microglia on axonal dieback.
Discussion
Our findings provide evidence that microglia are one of the
major factors inhibiting axonal regeneration in the CNS after SCI.
Furthermore, we have shown that this function of microglia is
mediated by RGMa. To our knowledge, this is the first report
identifying the molecule that is responsible for microglia-mediated
axonal growth inhibition.
Ours are not the only results highlighting the detrimental effects
of microglia after SCI [6,10]; however, a number of studies have
shown that microglia/macrophages can also have a positive effect
duringthis period [4,5].The conflict between these2 sets of findings
may stem from grouping together subsets of microglia/macrophag-
esthathavedistinctrolesduringneuronalregeneration.Specifically,
macrophages can be classified into at least 2 categories: ‘‘classically
activated,’’ or M1, and ‘‘alternatively activated,’’ or M2 [27,28].
The M1 phenotype produces a high quantity of pro-inflammatory
cytokines and free radicals that are essential for host defense, while
the M2 phenotype repairs tissues and reduces inflammation by
regulating the inflammatory response. This classification scheme
can also be applied to microglia [29].
Both M1 and M2 macrophages accumulate in the injured spinal
cord, but while M1 macrophages are neurotoxic, M2 macrophag-
Figure 4. RGMa mediates the effect of activated microglia in inhibiting neurite outgrowth. A, Results of Western blot for RGMa in
microglia. RGMa expression was higher in activated microglia (LPS) than in unactivated (control) or activated microglia treated with minocycline (LPS
+ mino). B, Quantitative data for A (n=3). C, Effect of treatment with anti-RGMa antibody on the neurite outgrowth-inhibiting effects of activated
microglia (n=3). D, Effect of treatment with anti-RGMa antibody on activated microglia-induced growth cone collapse (n=3). E, Results of Western
blot for RGMa in RGMa siRNA- and control siRNA-transfected microglia stimulated by LPS. F, Quantitative data for E (n=3). G, Relative length of
neurites of cortical neurons and that co-cultured with microglia, activated microglia stimulated by LPS, activated microglia transfected with control
siRNA (control siRNA), or activated microglia transfected with RGMa siRNA (RGMa siRNA) (n=3). H, Collapse assay (n=3). I, Results of Western blot for
neogenin in neogenin siRNA- and control siRNA-transfected cortical neurons. J, Quantitative data for I (n=3). K, Relative length of neurites of cortical
neurons transfected with control siRNA or neogenin siRNA, and that co-cultured with activated microglia stimulated by LPS (n=3). L, Collapse assay
(n=3). M, N, Effect of minocycline on activated microglia-induced neurite outgrowth inhibition (M, n=3) and growth cone collapse (N, n=3). Data are
represented as mean 6 SEM. *p,0.01 (B, C, D, G, H, K, L, M, N, one-way ANOVA followed by Tukey-Kramer test; F, J, Student’s t-test).
doi:10.1371/journal.pone.0025234.g004
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Expression of RGMa (green) by CD11b-positive microglia (red) in the lesion epicenter at 7 days after SCI. Scale bar: 20 mm. B, C, Changes in RGMa
expression in response to SCI (day 7) and treatment with minocycline (n=3). *p,0.01 (one-way ANOVA followed by Tukey-Kramer test). D–G,
Changes in the number of CD11b
+ cells (red) in an SCI lesion site at 7 (E) and 14 (G) days after treatment with minocycline. These patterns differ from
those observed after treatment with the control vehicle only (D, F). Scale bar: 500 mm. H, Results of quantitative analyses investigating CD11b-positive
area in minocycline-treated group (M) and vehicle-treated control (C) (7d, C, n=10; M, n=8; 14d, C, n=9; M, n=9). *p,0.05 (Student’s t-test). I–L,
Comparison of the effects of minocycline administration (J, L) and control vehicle treatment (I, K) on CST dieback at 7 and 14 days, respectively. CST
axons (BDA, green) and the accumulating microglial cells (CD11b, red). White line indicates the margin of lesion (see Materials and methods). Scale
bar: 100 mm. M, Quantitative analyses of CST dieback by minocycline treatment (M) and vehicle-treated control (C) (7d, C, n=10; M, n=8; 14d, C,
n=9; M, n=9). Data are represented as mean 6 SEM. *p,0.05 (Student’s t-test).
doi:10.1371/journal.pone.0025234.g005
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whether CNS macrophages are ultimately detrimental or helpful
to axonal regeneration after SCI. Indeed, it has been reported that
infiltrating monocyte-derived macrophages expressing interleukin
10 (M2) aid recovery from SCI [8]. Nevertheless, M1 becomes
increasingly more common as time elapses after SCI, ultimately
reducing neuronal survival and axonal growth [9].
In the current study, RGMa expression in microglia, and
therefore inhibition of neurite growth, was increased after the
primary microglia were stimulated by LPS, which promotes
differentiation into the M1 phenotype. Thus, our results highlight
one of the important effects of M1 phenotype and its molecular
mechanism detrimental to the lesion, i.e. RGMa-mediated
inhibition of axonal regeneration. In addition, our data show that
activated microglia, but not macrophages, inhibit axonal growth.
This partly contradicts the findings of Horn et al. (2008) [10], who
reported that activated macrophages, as well as activated
microglia, induce retraction of the dystrophic axons of dorsal root
ganglionic neurons. The discrepancy between these findings may
be a result of the fact that, whereas Horn et al. (2008) examined
dystrophic axons, our experiments focused on healthy cortical
neurons.
The results of our transwell culture assay suggest that cortical
neurons are not affected by factors secreted from microglia. This
observation is consistent with previous reports [10]; further, our
hypothesis that microglia-derived RGMa inhibits axonal regener-
ation in the CNS is supported by several previous findings. First,
RGMa inhibits axonal outgrowth and facilitates growth cone
collapse [16,17,21]. Second, RGMa levels increase after SCI, as a
result of increased expression by activated microglia/macrophages
(Figure 5A–C; [16]). Third, administration of anti-RGMa antibody
promotes axonal growth and functional recovery after SCI [16].
Fourth, minocycline treatment decreases the number of microg-
lia/macrophages and expression of RGMa, leading to suppression
of axonal retraction (dieback). In order to definitely demonstrate
the importance of RGMa in the process of axon regrowth
inhibition, future studies will need to investigate the impacts of
selectively deleting this gene from microglia.
We used minocycline to block the activation of microglia.
Treatment with minocycline improves functional outcome after
SCI [12,30–32]. The beneficial effects of minocycline are at least
partly dependent on suppression of cell death; for example,
minocycline prevents oligodendrocyte death by inhibiting proNGF
production in microglia [32], and is postulated to inhibit neuronal
cell death by attenuating TNF-a and NO production [33]. Like
Stirling et al. (2004) [12], we found that minocycline treatment
suppresses microglia/macrophage accumulation in SCI lesions
and reduces axonal dieback of the CST in a mouse model. More
importantly, we have also shown that minocycline rescues the
inhibitory role of activated microglia on axonal growth in vitro,
and that this effect is mediated through reduction of RGMa
expression.
To investigate whether minocycline treatment has noticeable
effects on mouse behavior, we evaluated the recovery of hindlimb
locomotor function using Basso mouse scale (BMS) scores for 2
weeks post-SCI. We did not detect any significant differences in
improvement between control and treated mice (data not shown),
a finding that is consistent with some reports [34,35], but
inconsistent with others [12,30–32]. This discrepancy may be
due to differences in experimental conditions, divergent functions
of microglia, and the effects of minocycline on other cells.
In our experimental paradigm, minocycline treatment sup-
pressed the retraction of CST but could not induce robust axonal
regeneration beyond the lesion or sprouting (Figure 5). Because
many inhibitory mechanisms are thought to collectively affect the
capacity for regeneration in adult CNS, a combinatory approach
that allows the elimination of a large number of inhibitory cues
[1,14] and the promotion of neurons’ intrinsic axon-growing
capacity [3] will be required to reconstruct the injured neural
network. Our study makes an important first step in this process by
elucidating the function of activated microglia and describing the
mechanism underlying their activity.
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